Oligonucleotide Synthesis Market Intelligence: Size, Share and Growth Outlook Through 2035

Market Overview

Overview

• The global oligonucleotide synthesis market was valued at USD 2.8 billion in 2025, supported by accelerating demand from pharmaceutical companies, biotechnology firms, and academic research institutions pursuing nucleic acid based drug development, molecular diagnostics, and advanced genomics research.
• The market is projected to reach USD 8.6 billion by 2035, expanding at a compound annual growth rate (CAGR) of 12.5% through the forecast period from 2026 to 2035, according to Brevintel analysis This growth trajectory is anchored in the structural expansion of oligonucleotide therapeutics pipelines, the broad integration of synthetic oligonucleotides across clinical and research workflows, and the accelerating commercialization of precision medicine and gene editing…
• At a fundamental level, oligonucleotide synthesis represents one of the most versatile enabling technologies in modern life sciences, providing the molecular building blocks for diagnostics, therapeutics, and synthetic biology applications that are reshaping healthcare and research globally.
• The sustained demand across these end use domains, combined with growing manufacturing investments by leading commercial synthesis providers, is expected to support double digit growth across the forecast horizon.

Market Dynamics

Overview

• Key Drivers
• Drivers Impact Analysis
• Expanding Applications in Molecular Diagnostics and Precision Medicine
• The increasing adoption of molecular diagnostic technologies and precision medicine frameworks has materially elevated demand for synthesized oligonucleotides across the global market.
• Synthetic oligonucleotides serve as foundational reagents in PCR, qPCR, next generation sequencing, liquid biopsy, and genetic testing workflows, functioning as primers, probes, hybridization capture reagents, and sequencing adapters.
• As healthcare systems across North America, Europe, and Asia Pacific transition toward individualized treatment protocols informed by patient level genomic data, demand for high quality custom oligonucleotides continues to rise substantially across both clinical diagnostics laboratories and biomedical research organizations.
• The convergence of companion diagnostics with pharmaceutical development has further expanded the synthesis market by creating dual demand for research grade and regulatory grade oligonucleotide products within the same drug development program.
• This driver is expected to contribute a CAGR impact of 2.1 to 2.6%.
• Growing Prevalence of Diseases Globally
• The rising incidence of chronic diseases, infectious diseases, genetic disorders, and cancer worldwide is intensifying the need for advanced diagnostic and therapeutic solutions that rely on synthesized oligonucleotides.
• Global health data underscores a persistent and growing disease burden across multiple therapeutic areas, compelling pharmaceutical companies and academic research centers to expand their use of oligonucleotide based technologies for early disease detection, biomarker identification, and targeted therapy development World Health Organization, who.int.
• The increasing recognition of oligonucleotide based approaches as viable treatment modalities for conditions previously considered difficult to address with conventional small molecule or biologic drugs is expanding the addressable patient population and, consequently, the commercial synthesis demand.

Segmentation Analysis

Segment Overview

• Oligonucleotide synthesis products and services account for 53% of the total market, representing the largest segment within the product type classification, with a projected CAGR of 12.05% through the forecast period from 2026 to 2035.
• This segment encompasses the core synthesis services offered by commercial providers, spanning research grade, analytical grade, and GMP grade oligonucleotides customized for specific sequence length, chemical modification, and purity requirements across diverse customer applications.
• The dominance of this segment reflects the essential and non substitutable nature of synthesis services as the primary commercial offering underpinning demand across all downstream application areas, from basic academic research to late stage pharmaceutical clinical development.
• At the segment level, the fastest growth is observed in GMP grade synthesis services for therapeutic applications, where regulatory requirements and technical complexity command premium pricing relative to standard research grade production.
• Leading synthesis platforms deployed by Thermo Fisher Scientific and Integrated DNA Technologies, including Ultramer long mer oligonucleotides and proprietary modified oligo product lines designed for gene editing and diagnostics applications, serve customers across the full quality spectrum and reinforce the dominance of the synthesis services sub segment as the market's primary revenue engine.
• The increasing complexity of oligonucleotide modifications, including phosphorothioate backbones, 2 prime O methyl modifications, and locked nucleic acid incorporation for therapeutic applications, is elevating the technical barriers to entry and supporting premium pricing for specialized synthesis providers capable of delivering complex modified sequences at commercial scale.
• The synthesis services segment is expected to retain its dominant position through the forecast period, driven by expanding pharmaceutical demand for GMP grade material and the growing adoption of modified oligonucleotides across diagnostics and synthetic biology applications.

Reagents and Consumables

• Reagents and consumables account for 33.10% of the total market and are expected to grow at a CAGR of 12.72%, reflecting the broad reliance of synthesis workflows on phosphoramidite monomers, coupling reagents, deprotection chemicals, purification resins, and quality control consumables consumed across both commercial synthesis operations and in house synthesis programs.
• This segment is closely linked to the growth of internal synthesis operations at pharmaceutical companies and large academic research centers that maintain their own synthesis infrastructure rather than relying entirely on external service providers.
• Merck's MilliporeSigma division supplies a comprehensive range of synthesis chemistry reagents, including modified nucleoside phosphoramidites and specialty coupling agents that enable production of chemically modified oligonucleotides, and represents one of the primary suppliers serving this segment globally.
• The reagents and consumables segment benefits from a recurring revenue model, as synthesis consumables are continuously replenished regardless of whether synthesis is performed in house or outsourced, creating a stable and growing revenue stream for chemistry suppliers.
• As the volume of oligonucleotide synthesis output increases across both commercial and in house settings, demand for upstream chemistry inputs scales proportionately, ensuring that growth in overall synthesis market volume translates directly into expanding reagent and consumable procurement.
• The increasing adoption of chemically complex modified oligonucleotides for therapeutic applications, which require specialty phosphoramidites not available from general chemistry suppliers, is supporting margin expansion in this sub segment and reinforcing the competitive position of specialized chemistry providers.

Equipment

• The Equipment segment represents 13.90% of the market with the highest projected CAGR of 13.58% among all product type sub segments, comprising automated DNA and RNA synthesizers, high performance liquid chromatography purification systems, and analytical instrumentation including mass spectrometry platforms used for quality control and batch release testing.
• The accelerating capital investment in synthesis automation and analytical instrumentation reflects the industry's transition toward higher throughput, reduced operator variability, and improved process consistency, with platforms from Agilent and other instrument manufacturers enabling scalable production from laboratory through commercial scale.
• The quality systems required for GMP compliance are driving substantial capital expenditure on validated analytical instrumentation, as synthesis providers must demonstrate comprehensive batch characterization capabilities to satisfy regulatory expectations for therapeutic oligonucleotide production.

Research

• The Research application segment holds the largest share within the application classification at 42.40%, growing at a CAGR of 11.63% through the forecast period from 2026 to 2035.
• Academic and industrial research applications encompass a broad spectrum of oligonucleotide use cases, including gene expression studies, protein binding assays, functional genomics, molecular cloning, CRISPR guide RNA design, and NGS library preparation, collectively driving high volume demand for diverse sequence types and modification formats.
• The volume of oligonucleotides consumed in research settings is substantial, driven by the high diversity of sequences required across experimental programs and the relatively streamlined purity requirements compared to clinical grade applications, which enables faster turnaround and more competitive pricing from commercial suppliers.
• Research institutions worldwide rely on established providers including Eurofins Genomics and Integrated DNA Technologies for rapid delivery, broad modification availability, and affordable pricing on both standard and modified sequences.
• Supply chain leads interviewed across Tier 1 synthesis providers servicing the research segment indicated that 60% of their academic and institutional customers had expanded oligonucleotide orders related to CRISPR functional screening by mid-2025, up from approximately 25% just 24 months earlier, reflecting the deepening integration of gene editing into standard research workflows.
• The research segment's growth, while comparatively lower than the therapeutics segment, is sustained by consistent demand expansion in synthetic biology, epigenomics, proteomics, and companion NGS technologies that collectively maintain strong volume demand for diverse oligonucleotide formats.

Therapeutics

• The Therapeutics segment accounts for 38% of total application revenue and is projected to expand at the highest CAGR of 13.25% among all application categories, underscoring its increasing strategic importance and the disproportionate revenue per unit it generates relative to research grade applications.
• This segment is anchored by the growing pharmaceutical pipeline of antisense oligonucleotide drugs, siRNA therapeutics, RNA aptamers, and emerging RNA based therapeutic formats targeting a wide range of disease indications including cancer, rare genetic disorders, cardiovascular diseases, and infectious conditions.
• The synthesis of therapeutic oligonucleotides demands adherence to stringent quality standards, including full GMP compliance, validated analytical testing protocols, impurity profiling, and rigorous batch documentation, which drive premium pricing and create durable competitive advantages for synthesis providers with validated GMP capabilities.
• Maravai LifeSciences and Eurogentec are among the specialized providers serving this high value segment with dedicated GMP synthesis suites, analytical services, and regulatory support capabilities designed to accompany pharmaceutical customers from early clinical development through commercial supply.
• The broader pipeline of over 100 active nucleic acid therapeutic clinical trials, combined with the continued commercial success of approved oligonucleotide drugs, is expected to sustain robust demand growth in this segment across the forecast period.
• The Therapeutics segment's structurally higher revenue per unit, driven by GMP compliance costs and the analytical complexity of therapeutic batch release, ensures that its revenue contribution will grow at a faster rate than its unit volume share within the overall application mix.

Diagnostics

• The Diagnostics segment represents 19.60% of the total market and is expected to grow at a CAGR of 12.78%, reflecting the expanding integration of molecular diagnostics into clinical laboratory practice and the diversification of diagnostic applications requiring custom synthesized oligonucleotides.
• This segment encompasses oligonucleotides used as diagnostic probes, hybridization capture reagents, fluorescently labeled primers, and quantitative PCR controls across molecular diagnostic platforms serving oncology, infectious disease, genetic disorder, and pharmacogenomics testing workflows.
• The expansion of liquid biopsy, companion diagnostics, and point of care molecular testing is expected to sustain demand growth in this segment, with providers including Thermo Fisher Scientific and LGC Biosearch Technologies supplying labeled probes and primer sets for both laboratory developed tests and commercially manufactured diagnostic kits meeting regulatory specifications.
• The diagnostics segment also benefits from the ongoing commercialization of spatial transcriptomics and single cell sequencing technologies, both of which require large volumes of custom capture probes and sequencing primers that must meet stringent quality and reproducibility standards.

Pharmaceutical and Biotechnology Companies

• Pharmaceutical and biotechnology companies constitute the dominant end use segment, representing 55% of total market revenue with a projected CAGR of 12.65% through the forecast period.
• This segment's leadership reflects the extensive and growing use of oligonucleotides across the pharmaceutical value chain, from early stage target validation and lead identification through preclinical testing, clinical manufacturing, and commercial scale drug substance production.
• Pharmaceutical companies are increasingly establishing long term supply agreements with GMP qualified synthesis providers to ensure continuity of supply for oligonucleotide based drugs in clinical trials, reflecting the strategic importance of synthesis reliability in drug development programs where supply chain disruption can directly impact patient enrollment and regulatory timelines.
• Major integrated pharmaceutical companies such as Merck have developed internal oligonucleotide synthesis capabilities while simultaneously engaging contract manufacturers, adopting a hybrid procurement model that balances supply security with cost efficiency.
• Global R&D investment in the life sciences sector has expanded consistently across major economies, continuing to underpin this segment's growth by sustaining the preclinical and clinical programs that generate oligonucleotide demand across the synthesis quality spectrum Organisation for Economic Cooperation and Development, oecd.org.

Academic and Research Institutes

• Academic and research institutes account for 21% of the market and are expected to grow at a CAGR of 12.24%, sustained by ongoing government funding for genomics research, expanding postgraduate and postdoctoral programs in life sciences, and growing cross institutional collaborations in synthetic biology, precision medicine, and computational biology.
• Research institutes often function as early adopters of new oligonucleotide chemistries and synthesis technologies, playing an important role in validating new product formats before broader commercial adoption by pharmaceutical and diagnostic customers.
• The segment's engagement with CRISPR functional genomics, single cell genomics, and RNA biology research is particularly strong, and these application areas have experienced above average demand growth over the preceding three to four years.
• Institutions in North America and Europe represent the largest academic demand centers, while emerging academic hubs in Asia Pacific, particularly in China, India, and South Korea, are experiencing accelerating growth supported by expanding national research budgets.

Contract Research Organizations

• Contract research organizations hold a 15.6% market share and are projected to grow at the highest end use segment CAGR of 13.27%, driven by the sustained and accelerating trend toward outsourcing of drug discovery and preclinical testing activities by pharmaceutical and biotechnology companies seeking to reduce fixed costs and access specialized expertise without internal infrastructure investment.
• CROs rely on a consistent supply of high quality oligonucleotides to support client programs spanning gene function studies, target engagement assays, biomarker validation, and ADME profiling, with rapid turnaround requirements creating strong demand for reliable commercial synthesis partners that can deliver standardized products within short order lead times.
• The growing sophistication of CRO oligonucleotide requirements, driven by increasing pharmaceutical client demands for complex modified sequences in preclinical programs, is elevating both the unit value and technical complexity of the CRO synthesis segment relative to the broader research category.
• Industry Q3 2024 research covering 340 procurement and operations leads at CROs across North America, Europe, and Asia Pacific, 74% reported increasing their oligonucleotide procurement over the preceding 18 months, with CRISPR applications, NGS library preparation, and therapeutic candidate profiling identified as the primary demand drivers.

Other End Users

• Other End Users, which include agricultural biotechnology companies, food safety testing laboratories, forensic science institutions, and environmental monitoring organizations, represent 8.40% of the market with a projected CAGR of 10.43%, reflecting their comparatively lower but steadily growing demand for customized oligonucleotide products across non pharmaceutical applications.
• Agricultural biotechnology companies utilize synthesized oligonucleotides for crop trait analysis, pathogen detection, and gene editing research in plants, while food safety and environmental testing laboratories rely on PCR primer sets and hybridization probes for regulatory compliance testing and contamination surveillance.
• Forensic institutions use oligonucleotides in DNA fingerprinting, identity verification, and crime scene analysis workflows, with demand in this sub segment linked to the expansion of national DNA databases and the increasing adoption of molecular forensic techniques in criminal justice systems across multiple geographies.

North America Oligonucleotide Synthesis Market

• North America represents the largest regional market for oligonucleotide synthesis, underpinned by an exceptionally well developed pharmaceutical and biotechnology industry concentrated primarily in the United States and a robust federal research funding infrastructure.
• The US accounts for the majority of regional revenue, supported by sustained NIH research funding, a high concentration of clinical stage biotechnology companies, and the presence of market leading oligonucleotide synthesis providers including Thermo Fisher Scientific, Integrated DNA Technologies, and Maravai LifeSciences.
• The FDA's regulatory approval of multiple oligonucleotide based therapeutic drugs, including nusinersen, inclisiran, and givosiran, has validated the clinical utility of this therapeutic class and encouraged expanded investment in GMP grade synthesis infrastructure, with multiple US based providers announcing facility investments exceeding USD 50 million between 2022 and 2025 to address growing pharmaceutical demand.
• Maravai LifeSciences expanded its GMP RNA and oligonucleotide synthesis capacity in San Diego, California in 2024 and 2025, adding dedicated synthesis suites and analytical infrastructure to serve the growing pipeline of nucleic acid therapeutic clinical programs.
• Canada contributes a growing share of regional demand, supported by expanding academic genomics research, federally funded precision medicine initiatives, and a biotechnology cluster concentrated in Toronto, Montreal, and Vancouver.

Europe Oligonucleotide Synthesis Market

• Europe represents a significant and well established market for oligonucleotide synthesis, with demand anchored by strong academic research traditions, a mature pharmaceutical manufacturing base, and growing investment in nucleic acid therapeutics development across the region.
• Germany, the United Kingdom, and France constitute the core of European demand, each hosting major research universities, biotechnology incubators, and pharmaceutical manufacturing operations that rely on commercial oligonucleotide synthesis services for discovery, preclinical, and clinical supply programs.
• The European Medicines Agency has progressively refined its regulatory pathway for oligonucleotide based therapeutics, providing clearer guidance on quality requirements and chemistry, manufacturing, and controls expectations that reduce development timeline uncertainty for clinical stage nucleic acid drug programs.
• Eurofins Genomics and Eurogentec, both headquartered within Europe, serve the regional market with comprehensive synthesis portfolios spanning research grade through GMP grade production and have each invested in capacity expansion to address growing therapeutic demand from regional pharmaceutical companies.
• The Netherlands and Spain have emerged as secondary growth markets within Europe, with expanding biotechnology ecosystems, growing contract research sectors, and increasing academic investment in synthetic biology and precision medicine research.
• A growing number of European pharmaceutical companies are collocating oligonucleotide synthesis capacity with formulation and drug product manufacturing to create integrated nucleic acid therapeutic development platforms, reflecting a strategic move toward vertical integration within the regional supply chain that is expected to reshape procurement patterns over the medium term.

Asia Pacific Oligonucleotide Synthesis Market

• Asia Pacific is the fastest growing regional market for oligonucleotide synthesis, driven by expanding research activity, government investment in biotechnology infrastructure, and rapid growth in the molecular diagnostics industry across China, India, Japan, South Korea, and Australia.
• The Chinese government's national biotechnology development plans have directed substantial funding toward domestic genomics programs, nucleic acid manufacturing capacity, and biotechnology company formation, supporting the rapid expansion of a domestic synthesis services market and positioning China as a major manufacturing hub for research grade oligonucleotides serving both domestic and international customers.
• GenScript, headquartered in China with operations extending across the US and Europe, has established a prominent synthesis services presence in the Asia Pacific region, providing custom oligonucleotides, gene synthesis, and RNA synthesis services to pharmaceutical and research customers across the region and globally.
• India represents a fast growing demand center, supported by the government's Genomics for Public Health in India program and expanding private sector investment in biotechnology and pharmaceutical manufacturing, with Indian CROs and generic pharmaceutical companies increasingly incorporating oligonucleotide based assays and molecular testing into their preclinical research and quality control workflows.
• Japan and South Korea continue to invest in precision medicine and diagnostic genomics infrastructure, with national health programs in both countries mandating the adoption of next generation sequencing and molecular diagnostic technologies in clinical practice, reinforcing demand for upstream synthesis services that supply the primers, probes, and adapters required in these workflows.

Latin America Oligonucleotide Synthesis Market

• Latin America represents an emerging market for oligonucleotide synthesis, with Brazil and Mexico identified as the primary demand centers within the region and Argentina contributing growing research sector demand.
• Brazil's domestic pharmaceutical and biotechnology industry has expanded meaningfully over the past decade, supported by the Brazilian government's investment in national genomics programs and the establishment of research centers focused on tropical infectious diseases, oncology, and rare genetic conditions where oligonucleotide based diagnostics and therapies have significant clinical relevance.
• The Brazilian national health system's increasing adoption of molecular diagnostics for infectious disease surveillance, cancer screening, and genetic disorder management is driving demand for synthesized oligonucleotides used as primers and probes in accredited clinical laboratory workflows.
• Mexico's growing biotechnology sector and expanding CRO industry are contributing incremental demand for research and diagnostics grade synthesis, with US based synthesis providers serving the Mexican market through direct export and regional distribution partnerships.
• Argentina's established academic research infrastructure in molecular biology supports a modest but growing domestic demand for research grade oligonucleotides, with several research institutions maintaining in house synthesis capabilities supplemented by commercial procurement for specialized and modified sequences.

Middle East and Africa Oligonucleotide Synthesis Market

• The Middle East and Africa region represents the smallest but progressively expanding market for oligonucleotide synthesis, with demand concentrated in Saudi Arabia, the UAE, and South Africa.
• Saudi Arabia's Vision 2030 initiative has directed investment toward healthcare modernization, genomics research infrastructure, and the development of a domestic biotechnology sector, creating growing demand for molecular diagnostic and research reagents including synthesized oligonucleotides in clinical and academic settings.
• The UAE has positioned itself as a regional hub for life sciences innovation, with investments in genomics research centers in Abu Dhabi and Dubai and growing partnerships between international pharmaceutical companies and regional healthcare organizations driving demand for diagnostic and research grade oligonucleotides.
• South Africa represents the largest demand center within sub Saharan Africa, with established academic research institutions conducting molecular biology research, infectious disease surveillance, and genetic disorder studies that require commercial oligonucleotide synthesis services from international suppliers.
• The region's growth over the forecast period will be primarily driven by the expansion of molecular diagnostics infrastructure across public health systems, increasing research funding from government and international development organizations, and the growing penetration of precision medicine frameworks in national healthcare strategies across Gulf Cooperation Council countries.

Competitive Landscape

Overview

• The market exhibits moderate concentration at the leading tier, with the top five players collectively accounting for approximately 55% of total market revenue. Thermo Fisher Scientific leads the market with a 15.2% share, consolidated through an extensive product portfolio spanning research grade through GMP grade synthesis, a global manufacturing infrastructure, and customer relationships embedded across pharmaceutical companies, academic institutions, contract research…
• Eurofins has established a strong market position in Europe and North America through its Eurofins Genomics brand, which provides rapid turnaround synthesis services for standard and modified oligonucleotides, gene synthesis, and sequencing services. The company's competitive strategy centers on operational efficiency, broad modification availability, and price competitiveness for research grade applications, positioning it as a preferred supplier for academic research…
• Merck's position in the oligonucleotide synthesis market is primarily driven by its reagents and chemistry portfolio through its MilliporeSigma brand, supplying phosphoramidites, coupling reagents, and specialty chemistry inputs to both commercial synthesis operations and in house synthesis programs at pharmaceutical and academic organizations, as well as directly providing custom synthesis through its custom oligo service arm. Agilent Technologies participates in the market…
• Beyond the top five, companies including LGC Biosearch Technologies, Integrated DNA Technologies, Twist Bioscience, Maravai LifeSciences, Bioneer, Eurogentec, and Azenta Life Sciences collectively compete for the remaining market share through differentiated service offerings encompassing specialty modification chemistry, GMP manufacturing, high complexity oligo pool production, and rapid turnaround research services. Industry Q4 2024 expert panel involving conversations…
• The competitive landscape has seen ongoing consolidation activity, with established players pursuing acquisitions of specialty synthesis providers to expand their capability sets and geographic reach. Mergers and partnerships within the contract development and manufacturing organization sector have further blurred the boundary between oligonucleotide synthesis and downstream drug substance manufacturing, as pharmaceutical companies increasingly seek integrated partners…
• Major players operating in the market are: Thermo Fisher Scientific, LGC Biosearch Technologies, Integrated DNA Technologies, Bioneer, Eurogentec, Azenta Life Sciences, Eurofins, Maravai LifeSciences, GenScript, Twist Bioscience, Merck, and Agilent.
• Thermo Fisher Scientific operates one of the broadest oligonucleotide synthesis platforms in the industry, spanning custom DNA and RNA synthesis, modified oligonucleotides, gene blocks, and GMP grade material for clinical and commercial pharmaceutical applications. The company's Invitrogen and Applied Biosystems brands are deeply embedded in research and diagnostic laboratory workflows globally, and its manufacturing scale enables competitive pricing for high volume standard…
• LGC Biosearch Technologies specializes in labeled oligonucleotides, fluorescent probes, and specialty chemistry for molecular diagnostics and genomics applications. The company is recognized for its Black Hole Quencher technology, which is widely deployed in real time PCR diagnostic assays and research workflows, and its custom probe synthesis services supply leading diagnostic kit manufacturers and research institutions across North America, Europe, and Asia Pacific. LGC…
• Integrated DNA Technologies offers a comprehensive synthesis catalog that includes standard oligos, Ultramer long oligonucleotides for difficult sequence and large insert applications, the Alt R CRISPR reagent product line for guide RNA synthesis and gene editing applications, and xGen sequencing library preparation components for next generation sequencing workflows. The company has built a strong market position in the research and academic segments through its combination…
• Bioneer is a South Korean oligonucleotide synthesis and life sciences tools company that provides custom DNA and RNA synthesis, gene synthesis, and RNAi products to research and pharmaceutical customers across Asia Pacific and international markets. The company has developed proprietary synthesis technologies and expanded its product range to include modified oligonucleotides for gene silencing, diagnostic, and therapeutic applications, positioning itself as a leading…
• Eurogentec, headquartered in Belgium with operations across Europe and North America, provides oligonucleotide synthesis, GMP manufacturing services, and peptide synthesis to pharmaceutical and biotechnology customers requiring clinical and commercial grade materials. The company's GMP synthesis capabilities, coupled with its analytical chemistry and quality assurance services, make it a preferred partner for European pharmaceutical companies developing nucleic acid…
• Azenta Life Sciences provides cold chain biospecimen management, genomic services, and oligonucleotide synthesis through its Genewiz brand, offering synthesis services that emphasize rapid turnaround for standard and modified oligonucleotides. The company maintains laboratory operations in North America, Europe, and Asia Pacific, providing research customers with geographically proximate synthesis capacity and integrated sequencing and genomics services through the same…